Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 12Recruiting 9Completed 4Terminated 3Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 20Biopsy 19Cyclophosphamide 8venetoclax 5Bevacizumab 5Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Cetuximab 4Azacitidine 4fludarabine phosphate 3fludarabine 3decitabine and cedazuridine drug combination 3X-Rays 3Radiosurgery 3Radiation 3Prednisone 3Doxorubicin 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2Tacrolimus 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × binimetinib × 90 days × Clear all
NCT05111561 2026-05-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡